Table 2.
Association of MPM Histologic Subtype With Second-Line Immune Checkpoint Inhibitor Therapy
| Unadjusted OR (95% CI) | p Value | Adjusted OR (95% CI)a,b | p Value | |
|---|---|---|---|---|
| Before NCCN guideline revisionc | ||||
| Epithelioid | 1 (reference) | 0.900 | 1 (reference) | 0.767 |
| Nonepithelioidd | 0.95 (0.45–2.01) | 1.12 (0.52–2.44) | ||
| After NCCN guideline revision | ||||
| Epithelioid | 1 (reference) | 0.021 | 1 (reference) | 0.006 |
| Nonepithelioid | 2.50 (1.15–5.41) | 3.26 (1.41–7.54) |
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; MPM, malignant pleural mesothelioma; NCCN, National Comprehensive Cancer Network.
Adjusted for age quartile (46–67, 68–73, 74–78, 79–84 y), sex (female, male), race (nonwhite, white), ECOG performance status (0–1, 2–4), center volume (low, high), and type of insurance (Medicare/Medicaid, commercial health plan, other).
Multiple imputation was used for missing ECOG performance status, race, and insurance data.
The NCCN guideline for MPM treatment was revised to include immune checkpoint inhibitor therapy as an option for second-line therapy on July 7, 2017.
Nonepithelioid histologic subtypes include sarcomatoid and biphasic MPM.